Showing results (51-60 of 98) with videos related to
Sort By:
Pageof 10
Therapeutic Advances in Medical Oncology|April 15, 2021
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037)Susana Banerjee, Holly Tovey, Rebecca Bowen, et al.The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.Breast Cancer Research : BCR|January 2, 2020
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patientsQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.Ebiomedicine|August 19, 2022
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancerMilana A Bergamino, Elena López-Knowles, Gabriele Morani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast CancerMitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, et al.JNCI Cancer Spectrum|July 31, 2019
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast CancerQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.Breast Cancer Research : BCR|April 3, 2016
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomasElena López-Knowles, Qiong Gao, Maggie Chon U Cheang, et al.Cancer Discovery|November 20, 2023
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast CancerBelinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, et al.Pageof 10